Innocare Pharma Limited (SSE: 688428) has announced that its independently developed next-generation TRK inhibitor Zorifertinib Tablets (brand name: Yinuoxin®) has been included in the new version of the National Medical Insurance Catalog, for the treatment of adult and adolescent patients aged 12 and above with solid tumors carrying NTRK fusion genes.

The new version of the National Medical Insurance Catalog will officially take effect on January 1, 2027. The agreement is valid from January 1, 2027 to December 31, 2028.